When should you add in a non-statin therapy?
New global guidance recommends when to use ezetimibe and PCSK9 inhibitors in hard-to-treat patients at high risk of a CVD event
New guidance should help doctors better manage hard-to-treat hypercholesterolaemia in patients at very high-risk of a cardiovascular event, say its authors.
In their BMJ paper, published earlier this month, the international panel of clinicians recommends when to use ezetimibe and/or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with high LDL cholesterol (LDL-C) who are on a the maximum dose of statins or are intolerant to them.
